Bariatric embolization is an interventional procedure performed with a view to inducing weight-loss in the treatment of obesity. Evidence from clinical trials suggests that the procedure is well tolerated and has a good safety profile. Early studies demonstrate a mild-moderate beneficial effect. However, further research is required to establish the efficacy of this treatment.
Most commonly this is performed via the splenic artery and selecting the left gastro-epiploic artery where the embolic agent (commonly microspheres) may be distributed.
- gastric ulceration
- gastric perforation
- splenic infarction
Preliminary studies of animal models 2,3 demonstrate histopathological evidence that the procedure reduces local ghrelin production which may serve as the underlying endocrine mechanism for weight loss.
- 1. Aldawudi I, Katwal PC, Jirjees S, Htun ZM, Khan S. Future of Bariatric Embolization: A Review of Up-to-date Clinical Trials. (2020) Cureus. 12 (5): e7958. doi:10.7759/cureus.7958 - Pubmed
- 2. Paxton B et. al. Bariatric embolization for suppression of the hunger hormone ghrelin in a porcine model. (2013) Radiology. doi:10.1148/radiol.12120242 - Pubmed
- 3. Weiss C et. al. Bariatric Embolization of Arteries for the Treatment of Obesity (BEAT Obesity) Trial: Results at 1 Year. (2019) Radiology. doi:10.1148/radiol.2019182354 - Pubmed